Back to top
more

Cosmos Health Inc. (COSM)

(Real Time Quote from BATS)

$0.89 USD

0.89
89,453

+0.03 (3.07%)

Updated Aug 4, 2025 10:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Fast-paced Momentum Stock Cosmos Health Inc. (COSM) Is Still Trading at a Bargain

by Zacks Equity Research

Cosmos Health Inc. (COSM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -13.04% and 12.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -17.91% and 99.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 54.39% and 21.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -77.78% and 2.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -61.90% and 0.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 29.41% and 12.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -14.29% and 2.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 2.50% and 6.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pyxis Oncology (PYXS) delivered earnings and revenue surprises of 77.78% and 279.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 29.63% and 41.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 9.30% and 3.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?